SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx ($ARDX) is trending amid widespread speculation following reports that Zydus Lifesciences is in talks to acquire a controlling stake or key assets, with the community actively discussing the potential for a significant buyout. This buzz is amplified by the recent extension of patents for IBSRELA and XPHOZAH until 2041 and bullish revenue projections, fundamentally altering valuation perspectives and putting pressure on short positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial was conducted by &nbsp;Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris.</li><li>The company said that once daily oral 50 mg Denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints in the study.&nbsp;</li><li>Ascletic said in October that it plans to submit a new drug application to China National Medical Products Administration for Denifanstat for the treatment of moderate-to-severe acne soon. &nbsp;</li></ul>Shares of Sagimet Biosciences Inc. (SGMT) soared 22% by Friday afternoon after its Denifanstat drug yielded positive results in the treatment of acne in a late-stage trial.The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. It was aimed at evaluating the safety and efficacy of Denifanstat in acne treatment.<h2 class="st-heading-2">Trial Takeaways</h2>Acne vulgaris is a common skin condition caused by clogged hair follicles from oil and dead skin cells, which can result in whiteheads, blackheads, pimples, and in severe cases, painful nodules and cysts.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sagimet.com/news-releases/news-release-details/denifanstat-achieved-all-endpoints-treatment-moderate-severe">said</a> that once daily oral 50 mg Denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints. Primary endpoints included the percentage change in total lesion count, and the percentage change in inflammatory lesion count, among others.At week 12, treatment success rates with Denifanstat were more than double those of placebo, with marked reductions in both inflammatory and non-inflammatory lesions, it noted.Furthermore, the drug was generally well-tolerated, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Ascletis said in October that it plans to soon submit a new drug application to China National Medical Products Administration for Denifanstat for the treatment of moderate-to-severe acne.Sagimet, meanwhile, is studying the drug in the treatment of metabolic dysfunction associated steatohepatitis, a serious form of liver disease, characterized by fat buildup, inflammation, and liver cell damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SGMT"> SGMT stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="SGMT's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SGMT's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded positive on the stock, citing the size of the Chinese market.<stembedurl>https://stocktwits.com/Mikrus36/message/633613843</stembedurl>SGMT stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gm-reportedly-lays-off-over-200-employees-days-after-raising-2025-earnings-guidance/cLGJFcKR3tb">GM Reportedly Lays Off Over 200 Employees Days After Raising 2025 Earnings Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study

The trial was conducted by  Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris.

DFAU
Dimensional ETF Trust - Dimensional US Core Equity Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAU News

DFAUDimensional ETF Trust - Dimensional US Core Equity Market ETF